Renin Angiotensin System Inhibition as treatment for Covid-19?

doi:10.1016/j.eclinm.2021.101023

. 2021 Jul:37:101023.

doi: 10.1016/j.eclinm.2021.101023. Epub 2021 Jul 13.

Renin Angiotensin System Inhibition as treatment for Covid-19?

Professor Bryan Williams¹

Affiliations

Affiliation

¹ Chair of Medicine, University College London Institute of Cardiovascular Science and Director, National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre.

PMID: 34278280
PMCID: PMC8275567
DOI: 10.1016/j.eclinm.2021.101023

Free PMC article

Renin Angiotensin System Inhibition as treatment for Covid-19?

Professor Bryan Williams. EClinicalMedicine. 2021 Jul.

Free PMC article

. 2021 Jul:37:101023.

doi: 10.1016/j.eclinm.2021.101023. Epub 2021 Jul 13.

Author

Professor Bryan Williams¹

Affiliation

¹ Chair of Medicine, University College London Institute of Cardiovascular Science and Director, National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre.

PMID: 34278280
PMCID: PMC8275567
DOI: 10.1016/j.eclinm.2021.101023

No abstract available

PubMed Disclaimer

Conflict of interest statement

Bryan Williams received honoraria from Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Menerini, and Servier for lectures on hypertension and is supported by the NIHR University College London Biomedical Research Centre, outside the submitted work.

Cited by

SARS-CoV-2 spike protein-ACE2 interaction increases carbohydrate sulfotransferases and reduces N-acetylgalactosamine-4-sulfatase by p38 MAPK.
Bhattacharyya S, Tobacman JK. Bhattacharyya S, et al. Signal Transduct Target Ther. 2024 Feb 14;9(1):39. doi: 10.1038/s41392-024-01741-3. Signal Transduct Target Ther. 2024. PMID: 38355690 Free PMC article.
Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19.
Ghimire B, Pour SK, Middleton E, Campbell RA, Nies MA, Aghazadeh-Habashi A. Ghimire B, et al. Biomedicines. 2023 Jul 27;11(8):2118. doi: 10.3390/biomedicines11082118. Biomedicines. 2023. PMID: 37626615 Free PMC article.
Network-Based Prediction of Side Effects of Repurposed Antihypertensive Sartans against COVID-19 via Proteome and Drug-Target Interactomes.
Kiouri DP, Ntallis C, Kelaidonis K, Peana M, Tsiodras S, Mavromoustakos T, Giuliani A, Ridgway H, Moore GJ, Matsoukas JM, Chasapis CT. Kiouri DP, et al. Proteomes. 2023 Jun 8;11(2):21. doi: 10.3390/proteomes11020021. Proteomes. 2023. PMID: 37368467 Free PMC article.
Haplotypic variants of COVID-19 related genes are associated with blood pressure and metabolites levels.
Gholami M, Zoughi M, Hasanzad M, Larijani B, Amoli MM. Gholami M, et al. J Med Virol. 2023 Jan;95(1):e28355. doi: 10.1002/jmv.28355. J Med Virol. 2023. PMID: 36443248 Free PMC article.
Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease.
Labarrere CA, Kassab GS. Labarrere CA, et al. Front Microbiol. 2022 Oct 6;13:979719. doi: 10.3389/fmicb.2022.979719. eCollection 2022. Front Microbiol. 2022. PMID: 36274722 Free PMC article. Review.

See all "Cited by" articles

References

1. Williams B, Zhang Y. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet. 2020;395:1671–1673. doi: 10.1016/S0140-6736(20)31131-4. - DOI - PMC - PubMed
1. de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Rodríguez-Puyol D; MED-ACE2-COVID19 study group Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705–1714. doi: 10.1016/S0140-6736(20)31030-8. - DOI - PMC - PubMed
1. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503–1511. doi: 10.1136/heartjnl-2020-317393. - DOI - PMC - PubMed
1. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275–284. doi: 10.1016/S2213-2600(20)30558-0. - DOI - PMC - PubMed
1. Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:254–264. doi: 10.1001/jama.2020.25864. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

[1] Williams B, Zhang Y. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet. 2020;395:1671–1673. doi: 10.1016/S0140-6736(20)31131-4. - DOI - PMC - PubMed

[2] Williams B, Zhang Y. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet. 2020;395:1671–1673. doi: 10.1016/S0140-6736(20)31131-4. - DOI - PMC - PubMed

[3] de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Rodríguez-Puyol D; MED-ACE2-COVID19 study group Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705–1714. doi: 10.1016/S0140-6736(20)31030-8. - DOI - PMC - PubMed

[4] de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Rodríguez-Puyol D; MED-ACE2-COVID19 study group Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705–1714. doi: 10.1016/S0140-6736(20)31030-8. - DOI - PMC - PubMed

[5] Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503–1511. doi: 10.1136/heartjnl-2020-317393. - DOI - PMC - PubMed

[6] Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503–1511. doi: 10.1136/heartjnl-2020-317393. - DOI - PMC - PubMed

[7] Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275–284. doi: 10.1016/S2213-2600(20)30558-0. - DOI - PMC - PubMed

[8] Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275–284. doi: 10.1016/S2213-2600(20)30558-0. - DOI - PMC - PubMed

[9] Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:254–264. doi: 10.1001/jama.2020.25864. - DOI - PMC - PubMed

[10] Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:254–264. doi: 10.1001/jama.2020.25864. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Renin Angiotensin System Inhibition as treatment for Covid-19?

Affiliation

Renin Angiotensin System Inhibition as treatment for Covid-19?

Author

Affiliation

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources